Covered recipient · General Payments record
SUZANNE M COLE
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
General Payments · PY2018–2024
$2,947.79
- Reported across 41 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $482.36 | 10 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| IMMUNITYBIO, INC. | $150.13 | 1 |
| Telix Pharmaceuticals | $148.58 | 1 |
| Tempus AI, Inc | $44.47 | 2 |
| Gilead Sciences, Inc. | $38.24 | 2 |
| AVEO Pharmaceuticals, Inc. | $27.16 | 1 |
| EISAI INC. | $26.13 | 1 |
| Adaptive Biotechnologies Corporation | $24.81 | 1 |
| Daiichi Sankyo Inc. | $22.84 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (10)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Adaptive Biotechnologies Corporation | $24.81 | 08/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150263147 | CMS |
| Aveo Pharmaceuticals, Inc. | $27.16 | 05/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143487310 | CMS |
| Daiichi Sankyo Inc. | $22.84 | 01/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1089410262 | CMS |
| Eisai Inc. | $26.13 | 06/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110784294 | CMS |
| Gilead Sciences, Inc. | $18.29 | 02/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133802614 | CMS |
| Gilead Sciences, Inc. | $19.95 | 03/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133802616 | CMS |
| IMMUNITYBIO, INC. | $150.13 | 05/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125508028 | CMS |
| Telix Pharmaceuticals | $148.58 | 01/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1081982266 | CMS |
| Tempus AI, Inc | $18.58 | 05/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150162850 | CMS |
| Tempus AI, Inc | $25.89 | 07/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150162852 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2020, 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.